In-FL-020
Phase 1Small molecule
In-FL-020 is one of 9 small molecule programs targeting mCRPC. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Mcrpc
#DrugCompanyPhaseTrials
1Xtandi
AstellasPhase 3
Cabometyx
Bristol-Myers SquibbPhase 3
Tecentriq
RochePhase 3
Talzenna
PfizerPhase 1
Lutetium Lu-177 PNT2002
JJonsson Comprehensive Cancer Center
Phase 2
Tazverik
EEpizyme, Inc.
Phase 1
ZEN003694
ZZenith Epigenetics
Phase 2
ONC-392
OOncoC4, Inc.
Phase 2
In-FL-020
FFull-Life Technologies GmbH
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for In-FL-020. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- FFull-Life Technologies GmbH